Jean-Paul Clozel is ready to pass the torch at his Actelion follow-up Idorsia, but he doesn’t want to walk away from the company altogether
Insomnia drugmaker Idorsia has released a new batch of data from an Alliance for Sleep survey showing a lack of sleep can put serious pressure on people’s relationships.
When J&J dropped $30 billion into an Actelion buyout back in 2017, it hoped the biotech’s pipeline would add something fresh to the massive drugmaker’s slow-to-grow portfolio. One of those mid-stage pickups, MS candidate ponesimod, is now ready for showtime in a busy and growing MS market.
Beyond Batten Disease Foundation (BBDF) has partnered with Actelion Pharmaceuticals, a Janssen company, to provide Zavesca (miglustat) for the development of BBDF-101, a proprietary combination of miglustat and trehalose to treat juvenile Batten disease (CLN3).
ALLSCHWIL, Switzerland--(BUSINESS WIRE)--Actelion Pharmaceuticals Ltd, a Janssen Pharmaceutical Company of Johnson & Johnson, today announced results from the Phase 3b TRITON trial, the first randomised controlled study evaluating the efficacy and safety of initial triple oral combination therapy (UPTRAVI® [selexipag], OPSUMIT® [macitentan] and tadalafil) compared to initial double oral combination therapy (placebo, macitentan and tadalafil) in newly diagnosed, treatment-naïve patients with pulmonary arterial hypertension (PAH). Study results were featured as an oral presentation as part of the digital European Society of Cardiology Congress held 29 August – 1 September 2020.
Full Fed. Circ. Won't Rehear Actelion Spinoff's Patent Term Bid
Swiss biotech Idorsia, spun out of Actelion after J&J wrapped up its $30 billion takeover in 2017, is one step closer to the finish line with a positive late-stage study of its insomnia drug.
The S1P1 rivalry in the multiple sclerosis arena is about to heat up substantially.
Actelion Pharmaceuticals Ltd, a Janssen Pharmaceutical Company of Johnson & Johnson, today announces new data evaluating initial combination therapy with OPSUMIT® (macitentan) and tadalafIl, a PDE5 inhibitor. Patients with pulmonary arterial hypertension (PAH, WHO Group 1) taking this combination showed hemodynamic improvement, as well as improvements in functional parameters and risk profiles. The combination was also well tolerated in these patients. The study data is being shared today at the CHEST Annual Meeting 2019, held October 19-23 in New Orleans, Louisian
J&J`s head-to-head PhIII data promise drug launch into crowded MS market